Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6758)	7/22/1998 10:03:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Once again you ignored my question. I bet that companies that have partnership agreements with others know how much of their product fits on the head of pin. They don't disclose to stockholders what their share of the profits will be because most shareholders are happy to see that they could make an agreement and get some up front financing and a small percent of sales. XOMA may get 100% of the income for sales of Neuprex for Meningococcemia and C.F., (if it works), but you still can't answer how much will fit on the head of pin nor what the cost of a full treatment will be. Guess I will have to stick with those biotechs that have sold their futures because I am at least smart enough to know the present is what counts. BTW Tharos is BPI of any use against gram positive bacteria?